Biogen ENVISION (Phase 3b/4)

Back to Drug Development Trials
Drug Development Trials

About the trial

WA only

Aducanumab, the investigational drug of this trial, was approved by the US FDA as a treatment for Alzheimer’s disease in June 2021. Approval was based on evidence that aducanumab reduces brain amyloid, coupled with evidence that the reduction in amyloid identified in aducanumab clinical studies is reasonably likely to predict clinical benefit in Alzheimer’s disease. This study is being conducted to fulfil a post marketing requirement from the FDA to verify the clinical benefit of aducanumab.

Who can be involved:

  • Male or female, aged 60 – 85 years inclusive, at the time of informed consent
  • MCI or mild Alzheimer’s disease
  • Have an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening

What is involved:

  • Monthly visits
  • 5 years trial duration
  • Monthly IV infusion
  • Must be able to tolerate MRI and PET scans
  • 33% chance of receiving a placebo

Additional info:

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email:

* Please note that participants in this study may have a chance of being placed on a placebo medication.